

Cannabis plant and resin

The Committee concluded that there is sufficient evidence to proceed to a Critical Review

Extracts and tinctures of cannabis

The Committee concluded that there is sufficient evidence to proceed to a Critical Review

Delta-9-THC

The Committee concluded that there is sufficient evidence to proceed to a Critical Review

Isomers of THC

The Committee concluded that there is sufficient evidence to proceed to a Critical Review


The recommendations and the assessments and findings on which they are based are set out in detail in the WHO Expert Committee on Drug Dependence *Fortieth report*. An extract of the report is attached in Annex 1 of this letter.

I would like to take this opportunity to inform you that the forty-first meeting of the ECDD will take place in November 2018. At that time, the Committee will undertake critical reviews of the above-mentioned cannabis components (cannabis plant and resin; extracts and tinctures of cannabis; Delta-9-THC; Isomers of THC) as well as of a number of New Psychoactive Substances (NPS), including fentanyl-analogues and other psychoactive substances.

I am very pleased with the ongoing collaboration between WHO, the United Nations Office on Drugs and Crime (UNODC) and the International Narcotics Control Board (INCB), in particular, how this collaboration has supported the work of the WHO Expert Committee on Drug Dependence, and more generally, the implementation of the operational recommendations of the United Nations General Assembly Special Session (UNGASS) 2016.

With my very best
personal regards.

Yours sincerely,



Dr Tedros Adhanom Ghebreyesus
Director-General